Imatinib

Use the mouse wheel or two fingers (on touchscreens) to zoom in and out of the map.

Map view:

Zoom: 100%

More settings

Connection length 100% Label size 100% Node size 100% Line width 100% Label width 100%

Export map as:

Imatinib topic overview

The analysis highlights History, Community, Culture and Applications as prominent areas in the source structure around Imatinib.

Related topics: 159
Source areas: 8
Connected nodes: 167
Extracted relationships: 158
Related term clusters: 31
Bridge connections: 167

What this topic covers Research coverage

Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.

Overview · 39 topics

Pharmacology · 26 topics

Interactions · 22 topics

History · 20 topics

Research · 18 topics

Medical uses · 16 topics

Side effects · 14 topics

Society and culture · 4 topics

Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.

Key facts & relationships

High-confidence facts extracted from structured source data. Use them as anchors for further research.

3D model (JSmol): Interactive image
AHFS/Drugs.com: Monograph
ATC code: L01EA01 (WHO)
Bioavailability: 98%
CAS Number: 152459-95-5 Y 220127-57-1 (mesilate)
ChEBI: CHEBI:45783 Y

Start with your topic. Discover where to go next.

Explore different angles and find fresh ideas to shape your next piece of content.

Imatinib

3Chronic myelogenous leukemia · Philadelphia chromosome · Tyrosine kinase

14Novartis · Targeted therapy · Cancer

14Bioavailability · Liver · Isozyme

9Active site · Binding site · Adenosine triphosphate

8Water retention (medicine) · Gastrointestinal bleeding · Bone marrow suppression

Explore all related topics Closing gaps

Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.

Medical uses

Side effects

Society and culture

Research

For the semantics nerds

You can skip this section if you’re here for content ideas and keyword inspiration.

Advanced semantic analysis

How Imatinib connects Entity context

The extracted context around Imatinib shows recurring relationship patterns in the source. For example, Imatinib → Anthony, Biological Studies, Brian Druker, British, California, Carlo Gambacorti-Passerini, Center, Charles Sawyers, Ciba-Geigy, CML, Elisabeth Buchdunger, Hammersmith Hospital, Hunter, Italy, John Goldman, Jürg Zimmermann, La Jolla, London, Memorial Sloan Kettering Cancer, Milano Bicocca Another extracted example is Imatinib → Abelson, ABL, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, FIP1L1-PDGFRalpha, Kit, Metabolism, N-demethylated, P450, PDGFR. Use these groups to spot repeated connection types before inspecting the individual relationships.

Top relations

related to history · 30

Imatinib → Anthony, Biological Studies, Brian Druker, British, California, Carlo Gambacorti-Passerini, Center, Charles Sawyers, Ciba-Geigy, CML, Elisabeth Buchdunger, Hammersmith Hospital, Hunter, Italy, John Goldman, Jürg Zimmermann, La Jolla, London, Memorial Sloan Kettering Cancer, Milano Bicocca

related to Pharmacokinetics · 13

Imatinib → Abelson, ABL, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, FIP1L1-PDGFRalpha, Kit, Metabolism, N-demethylated, P450, PDGFR

related to Other · 9

Imatinib → CHIC2, D816V, FIP1L1-PDGFRα, Gleevec, January, KIT, Ph, Philadelphia, The FDA

related to Economics · 8

Imatinib → Blood, Brian Druker, Carlo Gambacorti-Passerini, Druker, John Goldman, Novartis, Signatories, United States

related to Interactions · 8

Imatinib → Conversely, CYP2C9, CYP2D6, CYP3A4, Inactivated, Likewise, Since, St John's Wort

related to Medical uses · 8

Imatinib → ASM, CCyR, CML, DFSP, FDA, GISTs, MDS/MPD, MMR

related to Chronic myelogenous leukemia · 7

Imatinib → CML, Drug Administration, Due, FDA, Food, Philadelphia, Starting

related to Cardiotoxicity · 6

Imatinib → ABL, ABL1, Cardiotoxic, Clinical, Patient, Studies

Legal status · 5

Imatinib → AU: S4 (Prescription only), CA: ℞-only, EU: Rx-only, UK: POM (Prescription only), US: ℞-only

related to Gastrointestinal stromal tumors · 5

Imatinib → February, GIST, KIT-positive, KIT-positive GISTs, The FDA

Important terminology

Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.

Important terminology

novartis patent drug tyrosine gleevec treatment may use kinase also c-kit effects patients application bcr-abl mesylate growth used cyp3a4 chronic

Imatinib relationships Subject–Predicate–Object triples

TTTA extracted 158 structured relationships around Imatinib. Examples in this analysis include Imatinib → 3D model (JSmol) → Interactive image and Imatinib → AHFS/Drugs.com → Monograph. The table shows each extracted connection, where it came from and its confidence.

Subject	Predicate	Object	Confidence	Src
Imatinib	3D model (JSmol)	Interactive image	1.00	infobox
Imatinib	AHFS/Drugs.com	Monograph	1.00	infobox
Imatinib	ATC code	L01EA01 (WHO)	1.00	infobox
Imatinib	Bioavailability	98%	1.00	infobox
Imatinib	CAS Number	152459-95-5 Y 220127-57-1 (mesilate)	1.00	infobox
Imatinib	ChEBI	CHEBI:45783 Y	1.00	infobox
Imatinib	ChEMBL	ChEMBL941 Y	1.00	infobox
Imatinib	ChemSpider	5101 Y	1.00	infobox
Imatinib	CompTox Dashboard (EPA)	DTXSID3037125	1.00	infobox
Imatinib	Drug class	Tyrosine kinase inhibitor	1.00	infobox
Imatinib	DrugBank	DB00619 Y	1.00	infobox
Imatinib	ECHA InfoCard	100.122.739	1.00	infobox
Imatinib	Elimination half-life	18 h (imatinib) 40 h (active metabolite)	1.00	infobox
Imatinib	Excretion	Fecal (68%) and kidney (13%)	1.00	infobox
Imatinib	Formula	C29H31N7O	1.00	infobox
Imatinib	IUPHAR/BPS	5687	1.00	infobox
Imatinib	KEGG	D08066 Y	1.00	infobox
Imatinib	Legal status	AU: S4 (Prescription only)	1.00	infobox
Imatinib	Legal status	CA: ℞-only	1.00	infobox
Imatinib	Legal status	UK: POM (Prescription only)	1.00	infobox
Imatinib	Legal status	US: ℞-only	1.00	infobox
Imatinib	Legal status	EU: Rx-only	1.00	infobox
Imatinib	License data	US DailyMed: Imatinib	1.00	infobox
Imatinib	MedlinePlus	a606018	1.00	infobox
Imatinib	Metabolism	Liver (mainly CYP3A4-mediated)	1.00	infobox
Imatinib	Molar mass	493.615 g·mol−1	1.00	infobox
Imatinib	Other names	STI-571	1.00	infobox
Imatinib	PDB ligand	STI (PDBe, RCSB PDB)	1.00	infobox
Imatinib	Pregnancy category	AU: D	1.00	infobox
Imatinib	Pronunciation	ih-MAT-ih-nib	1.00	infobox

Related concept clusters Related term clusters

The concept neighborhoods around Imatinib bring nearby vocabulary together. In this analysis, examples include Treatment, Tyrosine and Mesylate. Use the clusters to find adjacent concepts and terminology that may deserve separate research.

Imatinib
- Treatment
- Tyrosine
- Mesylate
- Drug
- Kinase
- Effective
- C-kit
- Patent
- Novartis
- Inhibitor
- Cml
- Drugs
imatinib
- Treatment
- Tyrosine
- Mesylate
- Drug
- Kinase
- Effective
- C-kit
- Patent
- Novartis
- Inhibitor
- Cml
- Drugs
chronic myelogenous leukemia
- Leukemia
- Cml
- Used
- Mastocytosis
- Protein
- Effective
- Drugs
- Growth
- Kinase
- Treatment
- Liver
- Side
chronic eosinophilic leukemia
- Leukemia
- Cml
- Used
- Mastocytosis
- Protein
- Effective
- Drugs
- Growth
- Kinase
- Treatment
- Liver
- Side
drug itself
- Gleevec
- Liver
- Fda
- Cyp3a4
- Imatinib
- Effects
- Application
- Novartis
- Side
- Patent
- Protein
- Activity
food and drug administration
- Gleevec
- Liver
- Fda
- Cyp3a4
- Imatinib
- Effects
- Application
- Novartis
- Side
- Patent
- Protein
- Activity
rational drug design
- Gleevec
- Liver
- Fda
- Cyp3a4
- Imatinib
- Effects
- Application
- Novartis
- Side
- Patent
- Protein
- Activity
acute lymphocytic leukemia
- Cml
- Mastocytosis
- Protein
- Effective
- Drugs
- Used
- Growth
- Kinase
- Treatment
- Liver
- Side
- Active

Connections between topic areas Semantic bridges

For Imatinib, one of the stronger structural bridges in this analysis connects Imatinib with Overview. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.

Min side: 3

Imatinib — Overview · splits 128 ⟂ 40

Imatinib — Pharmacology · splits 141 ⟂ 27

Imatinib — Interactions · splits 145 ⟂ 23

Imatinib — History · splits 147 ⟂ 21

Imatinib — Research · splits 149 ⟂ 19

Imatinib — Medical uses · splits 151 ⟂ 17

Imatinib — Side effects · splits 153 ⟂ 15

Imatinib — Society and culture · splits 163 ⟂ 5

Map overview Semantic statistics

Imatinib

Nodes168

Edges167

Triples158

Avg. degree1.99

Density0.011905

Components1

Source & methodology

TTTA analyzes the structure around Imatinib to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as History, Community, Culture & Applications, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.

Source: Wikipedia — Imatinib · EN edition · Analysis: TopicsToTalkAbout

Imatinib: History, Community, Culture & Applications

Imatinib topic overview

What this topic covers Research coverage

Key facts & relationships

Start with your topic. Discover where to go next.

Questions to explore

Explore all related topics Closing gaps

Overview

Medical uses

Side effects

Interactions

Pharmacology

History

Society and culture

Research

For the semantics nerds

Advanced semantic analysis

How Imatinib connects Entity context

Imatinib

Top relations

Important terminology

Important terminology

Imatinib relationships Subject–Predicate–Object triples

Related concept clusters Related term clusters

Connections between topic areas Semantic bridges

Map overview Semantic statistics

Imatinib

Source & methodology